Orexo
Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap.
| Public | |
| Traded as | Nasdaq Stockholm: ORX |
| ISIN | SE0000736415 |
| Industry | Pharmaceutical |
| Founded | 1995 |
| Headquarters | Uppsala, Sweden |
Area served | Worldwide |
Key people | Nikolaj Sørensen (CEO) |
| Products | See list |
| Revenue |  |
 | |
Number of employees | 108 (2013) [1] |
| Website | Orexo.com |
| Footnotes / references Employee and financial data as of 2014 | |
The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000.[2] In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.[2]On March 29, 2019 a U.S. jury rejected a claim by Sweden’s Orexo AB that two generic opioid-addiction treatments created by Teva Pharmaceutical Industries Ltd. infringed a patent for Orexo’s biggest drug, Zubsolv.[3]
Products
- Abstral, for the treatment of breakthrough cancer pain. It was approved in 2008 in Europe and for marketing in United States by the FDA in 2011.[2]
- Edluar, for the treatment of short-term insomnia. FDA approved in 2009.[2]
- Zubsolv a dissolvable tablet which combines the drugs buprenorphine and naloxone and treats opioid dependency and addiction.[4] FDA approved in July 2013.[4] Launched in the United States in September 2013 [5]
gollark: osmarkshypotheticalstackconlang™ has a `do` operator, see.
gollark: However, this makes verbs into operators.
gollark: This was linked earlier.
gollark: Yes.
gollark: osmarkshypotheticalstackconlang™ too!
References
- "2013 Annual Report". Orexo. 2014. Retrieved October 12, 2014.
- "History". Orexo. Retrieved July 5, 2013.
- "Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug". 2019-03-29. Retrieved 2019-05-21.
- Toni Clarke (July 4, 2013). "U.S. FDA approves Orexo drug to treat opioid addiction". Reuters. Retrieved July 5, 2013.
- Press releases - Orexo
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.